Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Allergan | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Allergan

Botox, eye care drugs fuel growth

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Allergan 4Q13

4Q Revenues: $1.7 bilion (+14%)

4Q Earnings: $312 million (-4%)

FY Revenues: $6.3 billion (+12%)

FY Earnings: $989 million (-10%)

Comments: Specialty Pharmaceuticals revenues were up 14% to $1.4 billion in 4Q, with Botox contributing $526 million (+11%), and eye care pharmaceuticals adding $782 million (+11%). For FY13, Botox revenues were up 12% to $2.0 billion while eye care pharmaceuticals were up 7% to $2.9 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics